NOVOZYMES A/S SPONS.ADR 1 (NZM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NOVOZYMES A/S SPONS.ADR 1 (NZM) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€167.10 Million ≈ $195.36 Million USD) by net assets (€10.92 Billion ≈ $12.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NOVOZYMES A/S SPONS.ADR 1 (NZM) net asset quality to measure how much of total assets are equity-financed.
NOVOZYMES A/S SPONS.ADR 1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how NOVOZYMES A/S SPONS.ADR 1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NZM operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
NOVOZYMES A/S SPONS.ADR 1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NOVOZYMES A/S SPONS.ADR 1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Dtech Technology Co. Ltd. A
SHE:301377
|
N/A |
|
KONE Oyj
HE:KNEBV
|
0.129x |
|
Bank Mandiri Persero Tbk PT
JK:BMRI
|
-0.036x |
|
Verisk Analytics Inc
NASDAQ:VRSK
|
1.108x |
|
LPL Financial Holdings Inc
NASDAQ:LPLA
|
0.053x |
|
S.F. Holding Co. Ltd
SHE:002352
|
0.061x |
|
Repsol S.A
F:REPA
|
0.036x |
|
POP MART INT.GRP.DL-0001
F:735
|
N/A |
Annual Cash Flow Conversion Efficiency for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see NOVOZYMES A/S SPONS.ADR 1 market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.86 Billion ≈ $12.69 Billion |
€1.22 Billion ≈ $1.43 Billion |
0.113x | +23.31% |
| 2024-12-31 | €11.18 Billion ≈ $13.07 Billion |
€1.02 Billion ≈ $1.19 Billion |
0.091x | -68.46% |
| 2023-12-31 | €1.93 Billion ≈ $2.25 Billion |
€557.10 Million ≈ $651.31 Million |
0.289x | +2.75% |
| 2022-12-31 | €1.91 Billion ≈ $2.23 Billion |
€537.65 Million ≈ $628.57 Million |
0.282x | -15.39% |
| 2021-12-31 | €1.64 Billion ≈ $1.92 Billion |
€546.17 Million ≈ $638.53 Million |
0.333x | -- |
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more